

# 267 cGAS-STING Antagonists

## ► Asset Overview

<b>Product Type</b>	Small Molecule
<b>Indication</b>	Autoimmune disorders
<b>Current Stage</b>	Hit
<b>Target(MoA)</b>	STING-cGAS Inhibition (type I interferonopathies)
<b>Brief Description</b>	<ul style="list-style-type: none"><li>• cGAS-STING is a cytosolic DNA sensor pathway which activates innate immune response</li><li>• Gain-Of-Function mutations cause rare type I IFN auto-immune disorders.</li><li>• Hyper-activation of cGAS-STING in more common type I interferonopathies (Lupus, RA, ...)</li><li>• Emerging role in age-related disorders associated with chronic sensing of cytosolic DNA (myocardial infarction, lung inflammation, neurodegeneration/neuroinflammation, and tumorigenesis/metastasis)</li><li>• STING &amp; cGAS HTS performed &amp; hit selection ongoing</li></ul>
<b>Organization</b>	Centre for Drug Design and Discovery

# 267 cGAS-STING Antagonists

## ► Intellectual Property

Patent No.	
Application Date	
Status	
Country	

## ► Contact Information

Contact Person	Stefaan Allemeersch
Email	<a href="mailto:stefaan.allemeersch@cistim.be">stefaan.allemeersch@cistim.be</a>
URL	<a href="http://www.cd3.eu/pipeline/">http://www.cd3.eu/pipeline/</a>